Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure
This article was originally published in The Pink Sheet Daily
Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.
You may also be interested in...
Bristol-Myers Squibb has halted study of its Phase II nucleoside polymerase inhibitor for hepatitis C due to one trial patient suffering heart failure. It remains unclear if that event is related to the study drug, but do repeated toxicity issues with “nucs” indicate a class effect?
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
The year's biggest M&A deal, along with billion dollar alliances marked out December's dealmaking credentials.